Medlab Clinical (Medlab Clinical) Cash, Cash Equivalents, Marketable Securities : $0.21 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical Cash, Cash Equivalents, Marketable Securities?

Medlab Clinical's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 ($1.86 Mil) to Jun. 2023 ($0.15 Mil) but then increased from Jun. 2023 ($0.15 Mil) to Dec. 2023 ($0.21 Mil).

Medlab Clinical's annual cash, cash equivalents, marketable securities declined from Jun. 2021 ($10.27 Mil) to Jun. 2022 ($3.65 Mil) and declined from Jun. 2022 ($3.65 Mil) to Jun. 2023 ($0.15 Mil).

Medlab Clinical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Medlab Clinical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Cash, Cash Equivalents, Marketable Securities Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

7.95

6.26

10.27

3.65

0.15

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial												8.03	3.65	1.86	0.15	0.21

Medlab Clinical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Medlab Clinical (OTCPK:MDBBF) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Medlab Clinical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (Medlab Clinical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.